These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 35343254)

  • 1. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.
    Ren Y; Guo Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    Cancer Control; 2022; 29():10732748221076806. PubMed ID: 35343254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
    Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.
    Shi X; Wang Y; Ren J; Han X; Bi Y
    BMC Cancer; 2023 Nov; 23(1):1144. PubMed ID: 38001447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.
    Ren Y; Liu Z; Makamure J; Kan X; Song S; Liu Y; Qian K; Zheng C; Liang B
    Technol Cancer Res Treat; 2022; 21():15330338221131385. PubMed ID: 36259117
    [No Abstract]   [Full Text] [Related]  

  • 6. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.
    Guo Y; Ren Y; Chen L; Sun T; Zhang W; Sun B; Zhu L; Xiong F; Zheng C
    BMC Cancer; 2022 Mar; 22(1):270. PubMed ID: 35287627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study.
    Ren Y; Liu Y; Song S; Zheng C
    Cancer Control; 2024; 31():10732748241275004. PubMed ID: 39163892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
    Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
    Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of camrelizumab plus transarterial chemoembolization on massive hepatocellular carcinoma.
    Zhang S; Zhao Y; He L; Bo C; An Y; Li N; Ma W; Guo Y; Guo Y; Zhang C
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101851. PubMed ID: 34923180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.
    Jin ZC; Zhong BY; Chen JJ; Zhu HD; Sun JH; Yin GW; Ge NJ; Luo B; Ding WB; Li WH; Chen L; Wang YQ; Zhu XL; Yang WZ; Li HL; Teng GJ;
    Eur Radiol; 2023 Dec; 33(12):8669-8681. PubMed ID: 37368105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.
    Zhang JX; Chen YX; Zhou CG; Liu J; Liu S; Shi HB; Zu QQ
    Can J Gastroenterol Hepatol; 2022; 2022():7982118. PubMed ID: 35586608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinoma.
    Hou C; Xiong B; Zhou L; Fei Y; Shi C; Zhu X; Xie T; Wu Y
    BMC Cancer; 2024 Mar; 24(1):387. PubMed ID: 38539150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.
    Zhang JX; Hua HJ; Cheng Y; Liu S; Shi HB; Zu QQ
    Acad Radiol; 2024 Apr; 31(4):1304-1311. PubMed ID: 37775449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study.
    Duan X; Li H; Kuang D; Chen P; Zhang K; Li Y; He X; Xing C; Wang H; Liu Y; Xie L; Zhang S; Zhang Q; Zhu P; Dong H; Xie J; Li H; Wang Y; Shi M; Jiang G; Xu Y; Zhou S; Shang C; Ren J; Han X
    Hepatol Int; 2023 Aug; 17(4):915-926. PubMed ID: 37012542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm).
    Xiang Z; Li G; Mu L; Wang H; Zhou C; Yan H; Huang M
    Technol Cancer Res Treat; 2023; 22():15330338231200320. PubMed ID: 37723998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma.
    Sun B; Chen L; Lei Y; Zhang L; Sun T; Liu Y; Zheng C
    Br J Radiol; 2024 Jun; 97(1159):1320-1327. PubMed ID: 38711192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The second-line treatment of hepatocellular carcinoma with CalliSpheres drug-eluting bead transarterial chemoembolization combined with regorafenib: A safety and efficacy analysis.
    Liu S; Liu C; Wang Q; Liu Y; Wang D; Zhao G; Yu G
    Ir J Med Sci; 2024 Jun; 193(3):1215-1222. PubMed ID: 38300460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.
    Jiang N; Zhong B; Huang J; Li W; Zhang S; Zhu X; Ni C; Shen J
    Front Immunol; 2023; 14():1205636. PubMed ID: 37583693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.